Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingObservational

Utilization of the Natural History of Medullary Thyroid Carcinoma to Inform Advanced Disease Management

NCT ID: NCT04216732Sponsor: M.D. Anderson Cancer CenterLast updated: 2026-03-05

Summary

This study utilizes a multi-institutional registry to describe the natural history of medullary thyroid cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) in understanding disease management. The goal of this study is to learn about how medullary thyroid cancer develops and progresses.

Detailed description

PRIMARY OBJECTIVES: I. To describe the natural history of medullary thyroid cancer (MTC) using a comprehensive battery of demographic, clinical, pathologic, and genotypic variables collected in our existing multi-institutional patient registry. Ia. To describe the demographic, clinical, pathologic, and genotypic variables associated with each phase of disease. Ib. To identify those variables which are predictors of progression to the most advanced phases of disease that require small molecule therapy, including commercially approved and experimental agents. II. To characterize patients' experience with the different phases of MTC through a systematic evaluation of patient-reported outcomes (PROs). IIa. To describe clinical, psychosocial, economic, and physical well-being variables and the subsequent impact on quality of life associated with each phase of disease. IIb. To evaluate longitudinal changes in clinical, psychosocial, economic, and physical well-being variables between and within all phases of MTC, and the subsequent impact they have on quality of life. III. To evaluate the association of selected biometric and patient-reported outcomes on adherence, change, and discontinuation of approved targeted therapies and drugs being tested within clinical trial. OUTLINE: AIM I \& II: Patients complete questionnaires over 10-40 minutes 2-4 times per year about health and how finances and quality of life effect experience with disease. AIM III: Patients complete a questionnaire over 2 minutes and undergo blood pressure measurements every day for up to 12 weeks. The questionnaire data gets paired with the collected medical record history that is maintained in the Registry.

Arms & interventions

  • OtherBlood Pressure Measurement

    Undergo blood pressure measurement

  • OtherQuestionnaire Administration

    Complete questionnaires

Outcome measures

Primary

  • Natural history of medullary thyroid cancer (MTC)

    Will describe the natural history of MTC using comprehensive battery of demographic, clinical, pathologic, and genotypic variables collected in existing multi-institutional patient registry.

    Time frame: Up to 4 years

  • Patients' experience with the different phases of MTC

    Will characterize patients' experience with the different phases of MTC through a systematic evaluation of patient-reported outcomes (PROs).

    Time frame: Up to 4 years

  • Association of selected biometric and patient-reported outcomes

    Will evaluate the association of selected biometric and patient-reported outcomes on adherence, change, and discontinuation of approved targeted therapies and drugs being tested within clinical trial.

    Time frame: Up to 4 years

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Aims 1 and 2: A diagnosis of MTC * Aims 1 and 2: A registrant in the Medullary Thyroid Cancer Registry (MTCR). Patients of all disease phases will be eligible for enrollment * Aim 3: A diagnosis of advanced phase (red or gray) MTC as determined by clinical team * Aim 3: A current registrant in the MTCR

Study locations (2)

University of California San Francisco

San Francisco, California, 94143

Recruiting
Julie A. Sosa · Contact
Julie A. Sosa · Principal Investigator

M D Anderson Cancer Center

Houston, Texas, 77030

Recruiting
Elizabeth G. Grubbs · Contact
Elizabeth G. Grubbs · Principal Investigator
Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management | Cancerify